The FDA’s recent approval of OZEMPIC highlights the expanding use of GLP-1 drugs beyond diabetes and weight management. Novo Nordisk’s blockbuster medication has gained another label expansion, now ...

After its potential kidney disease drug went down in flames late last year, Novo Nordisk is pinning the blame on alleged ...

A lawsuit filed in the Singapore International Commercial Court is seeking $830 million in damages from KBP, with Novo ...

A popular diabetes drug just got a major new approval — and it could be a game-changer for millions of Americans at risk for kidney failure.

Ozempic is synonymous with weight loss for many people. Doctors explain benefits and risks of semaglutide and other GLP-1 ...

“Chronic kidney disease is a global healthcare problem ... including whether some medicines may pose a threat. Novo Nordisk's Ozempic has become the first drug in the GLP-1 class to be cleared ...

Semaglutide — the active ingredient in the brand-name meds Ozempic, Wegovy, and Rybelsus — treats type 2 diabetes and obesity ...

Ozempic was also FDA-approved to reduce the risk of cardiovascular death and worsening kidney disease in adults living with chronic kidney disease and type 2 diabetes. According to Novo Nordisk ...

Over 40% of U.S. adults meet the medical classification for obesity, according to the Centers for Disease Control and ...

The FDA has approved Ozempic (semaglutide) to reduce the risk of kidney disease worsening and cardiovascular death in those with T2D and CKD.

Whether you use Ozempic for type 2 diabetes, kidney disease (if you also have type ... This condition can also occur with chronic (long-term) alcohol use. To lower the risk of pancreatitis ...

So is Ozempic safe? Novo Nordisk, the pharmaceutical company ... “I understand there is an argument that obesity is a chronic disease like hypertension, diabetes, and once you need to be ...